We investigated agreement between selfreported prenatal alcohol exposure (PAE) and objective meconium alcohol markers to determine the optimal meconium marker and threshold for identifying PAE.
sumption, data validating analyte cutoffs and interpretation criteria are limited.
FAEE are formed from endogenous free fatty acids and ethanol by specific and nonspecific enzymes in blood and several tissues (19 ) . FAEE do not cross the placenta; therefore, meconium FAEE result exclusively from fetal synthesis (20 ) . Some individuals recommend summing 7 meconium FAEE (ethyl linolenate, palmitoleate, arachidonate, linoleate, palmitate, oleate, and stearate) and using a Ն2-nmol/g cutoff for heavy PAE (9, 10 ) , whereas others sum fewer FAEE (11, 21 ) . Summations often eliminate individual FAEE variability, although 1 report demonstrated that ethyl oleate and ethyl linoleate meconium concentrations alone distinguished women drinking Ն7 drinks per drinking day (DPDD) from those drinking fewer (8 ) .
EtG is produced by UDP-glucuronosyltransferasecatalyzed conjugation of ethanol and glucuronic acid, whereas EtS results from ethanol and activated sulfate conjugation by sulfotransferases (22 ) . Unlike FAEE, meconium EtG is primarily of maternal origin, as EtG readily crosses the placenta and fetal glucuronidation capacity is limited (23, 24 ) . Although relatively little is known about placental EtS transfer, evidence of variable yet substantial fetal sulfotransferase activity (25 ) suggests that meconium EtS may be of fetal origin.
There are many published meconium FAEE reports, but far fewer for EtG and EtS. Previously proposed meconium EtG cutoffs were suggested on the basis of meconium FAEE results; therefore, meconium FAEE limitations and biases influenced these suggested cutoffs, including 111 (16) , 200 (16) , 274 (11) , 333 (14) , and 444 (12) ng/g (0.5-2 nmol/g). Meconium EtG and EtS quantification may be superior to FAEE due to improved stability in meconium (26 ) and insensitivity to maternal diet variation. Most FAEE in authentic meconium show degradation after 12 h at room temperature and 72 h at 4°C, with large interindividual variability observed (26 ) . Additionally, freeze/thaw stability experiments have shown EtG and EtS concentrations Յ11% of initial results (13, 17, 26 ) . These results suggest that FAEE may not be adequate long-term meconium alcohol markers due to degradation susceptibility arising from environmental conditions. Additionally, Chan et al. reported that olive oil consumption during pregnancy was associated with increased total meconium FAEE (9 ) .
Clearly, more research is needed to validate meconium EtG and EtS cutoffs against reliable self-report measures. Our objective here was to evaluate agreement between self-reported PAE and meconium alcohol markers. With meconium results as the objective gold standard condition, we determined clinical sensitivity and specificity performance characteristics with self-reported PAE.
Materials and Methods

PARTICIPANTS
The Safe Passage Study of the Prenatal Alcohol in Sudden Infant Death Syndrome (SIDS) and Stillbirth (PASS) Network is a prospective study of 12 000 motherfetus/infant dyads, enrolled during pregnancy and followed for 1 year after birth. The primary objective is to determine the relationship between PAE, stillbirth, and SIDS (27 ) . We recruited women at high risk for poor pregnancy outcomes and drinking during pregnancy in the US Northern Plains and Cape Town, South Africa, representing 3 diverse populations: American Indians, mixed ancestry, and white (4, 5, 27 ) . On the basis of maternal self-report, 108 meconium samples were selected for this meconium alcohol marker investigation in the following categories: (a) no alcohol consumption at any time during pregnancy (n ϭ 33); (b) mean thirdtrimester (Ͼ24 weeks) DPDD Ͼ10 (n ϭ 14); (c) mean third-trimester DPDD 3-10 (n ϭ 32); (d) mean thirdtrimester DPDD 0 -Ͻ3 (n ϭ 10); or (e) any drinking during the first or second trimesters with no drinking reported during the third trimester (n ϭ 19). All meconium samples were collected within 48 h of birth (some at participants' homes) and refrigerated as soon as possible. Once obtained by the study sites, samples were immediately frozen (ՅϪ20°C) at study sites and remained frozen until analysis. Samples were transported on dry ice.
MATERNAL SELF-REPORT
We determined self-reported PAE by the timeline followback (TLFB) method (28 ), a structured, calendar-based interview collecting detailed ethanol consumption data for each drinking event with respect to alcohol type, container size, sharing, and duration (29 ) . The interview was modified for PASS (27 ) and administered at recruitment (between 6 weeks' gestation and through but not including delivery), each prenatal visit (20 -24, 28 -32 , and 34 -38 weeks), and 1 month postdelivery. At recruitment, women were interviewed about alcohol consumption the year before pregnancy and around conception (15 days before and after last menstrual period). At other visits, the reporting period was the 30 days before the last drinking day (LDD), if the participant consumed alcohol since her last visit. We collected detailed information on alcohol brand and drink volume consumed to accurately calculate total alcohol grams consumed. We calculated the number of standard DPDD from total alcohol grams consumed each drinking day, on the basis of the US standard drink definition of 14 g ethanol (29 ) . Local standard clinical practices determined gestational age (GA) at each site. Exposure timing was determined from GA at time of maternal report. Because meconium forms between gestational weeks 12 and 20 (30 ), we evaluated meconium alcohol marker detection with maternal selfreport at GA Ն19 weeks to account for potential GA measurement variability at the later meconium formation time (20 weeks). Additional measures were created with self-reported PAE at Ն12, Ն20, and Ն28 weeks' gestation (a more recent definition of the third trimester adopted by PASS after initial meconium sample selection). All measures included self-reported drinking categorization and DPDD.
MECONIUM ANALYSIS
We quantified 9 FAEE (ethyl laurate, ethyl myristate, ethyl linolenate, ethyl palmitoleate, ethyl arachidonate, ethyl linoleate, ethyl palmitate, ethyl oleate, and ethyl stearate), EtG, and EtS from a single 0.1-g meconium sample with a validated liquid chromatography tandem mass spectrometry method (26 ) . Limits of quantification (LOQs) were 25-50 ng/g for FAEE, 5 ng/g for EtG, and 2.5 ng/g for EtS. Sample preparation involved methanolic homogenization with wooden applicator sticks and solid-phase extraction (26 ) . Meconium was thoroughly mixed before sampling to ensure a representative sample. Previously, triplicate sampling from 3 positive sources across 3 test conditions demonstrated intrasubject variability 0.7%-17.6% (26 ) .
STATISTICAL ANALYSIS
We investigated distributions of continuous meconium biomarkers and exposure variables with KolmogorovSmirnov tests and visual boxplot inspection. Bivariate associations between self-reported exposure measures and meconium biomarkers were assessed with scatterplots, t tests, 2 tests, and Spearman correlations; among meconium biomarkers, Spearman correlations were used. Agreement between maternal self-report and meconium biomarkers was evaluated with statistics and corresponding 95% CIs. With meconium markers as the gold-standard condition, we calculated clinical sensitivity and specificity performance characteristics and corresponding 95% CI with self-reported drinking Ն19 weeks' gestation as the test. Sensitivity was defined as the number of women reporting drinking Ն19 weeks whose infants' meconium marker concentrations were at or above the cutoff, divided by all infants with meconium marker concentrations at or above the cutoff (true positives/true positives ϩ false negatives). Specificity was defined as the number of women who did not report drinking after 19 weeks' gestation and whose infants' meconium marker concentrations were below the cutoff, divided by all infants with meconium marker concentrations below the cutoff (true negatives/true negatives ϩ false positives). To evaluate a dose-response effect with DPDD, 4 variables were created for reported DPDD after 19 weeks' gestation: 0 DPDD, 0 to Յ3 DPDD, Ͼ3-10 DPDD, and Ͼ10 DPDD. Multiple logistic regression analysis was performed associating the meconium marker with the best clinical sensitivity and specificity performance with the 4 variables representing increasing self-reported DPDD (with no DPDD as the reference group), adjusting for GA reported at LDD or nondrinking day. Model discrimination and calibration were assessed with the c-statistic and Hosmer-Lemeshow test, respectively. Analyses were performed with SAS/ STAT software, version 9.3. All analyses used a 2-sided test for statistical significance with P Ͻ 0.05, except where discussed.
Results
PARTICIPANTS
Of the 108 women selected, 107 had maternal selfreported PAE information available at 19 weeks' gestation. Thirty-three women reported no alcohol consumption during pregnancy, 16 drank early in pregnancy with cessation by week 19, and 58 continued drinking beyond week 19, with 45 drinking in their third trimester (24% of women reported drinking within 1 month of delivery). Women drinking after 19 weeks reported 5.6 (5.3) and 4.7 (4.7) DPDD in the second and third trimesters, respectively.
MECONIUM ALCOHOL MARKER PREVALENCE AND
CONCENTRATIONS
More samples were positive for EtG (65.4%) than for EtS (21.5%), each of the 9 FAEE alone (10.3-52.3%), and the 3 FAEE summations at our LOQs (Table 1) . The proposed (9, 10 ) meconium 7 FAEE summation (excluding ethyl laurate and myristate) cutoff Ն2 nmol/g identified 25 (23.4%) infants, whereas the 4 FAEE summation (ethyl myristate, palmitate, oleate, and stearate), currently used in hair testing (31 ), identified 37 (34.6%).
Eighteen samples were both EtS and EtG positive; EtG concentrations (19 -103 716 ng/g) were 3.3-2151 times greater than EtS concentrations (2.8 -408 ng/g), with a median 285.3 EtG/EtS ratio. There were 5 EtSpositive, EtG-negative samples. In 4 of the 5 cases, EtS was the only detectable marker, and concentrations ranged from 3.2 to 13 ng/g. In the fifth case, 61 ng/g EtS was detected with 13.9 nmol/g summed 7 FAEE.
Spearman correlations between individual and summed meconium alcohol marker concentrations showed that EtG was not associated with meconium EtS concentrations and only weakly or negligibly ( Ͻ 0.5) (32 ) associated with individual and summed FAEE concentrations (Table 2 ). An exceptionally strong correlation ( Ն 0.9) was seen between FAEE summations and ethyl linoleate and ethyl oleate, indicating that these analytes dominated summation calculations. Most other individual FAEE associations were strong to moderate ( ϭ 0.5-0.899) (32 ) . Despite the many moderate/weak correlations, nearly all correlations (85.7%) were significant (P Ͻ 0.05/14), on the basis of our Bonferroni-corrected family-wise ␣ level (Table 2) .
AGREEMENT BETWEEN SELF-REPORTED EXPOSURE AND MECONIUM MARKERS
The meconium marker with the highest agreement with self-reported PAE Ն19 weeks was EtG Ն30 ng/g, with a value of 0.57 (95% CI 0.41-0.73), signifying moderate to substantial agreement (Table 3) . Individual FAEE at their LOQs had values Յ0.24, indicating only slight agreement. In comparison, both FAEE combinations of all 9 and 7 FAEE (excluding ethyl laurate and myristate) at Ն2 nmol/g demonstrated lower agreement with self-reported PAE than individual FAEE markers or the summation of 4 FAEE (ethyl myristate, palmitate, oleate, and stearate) Ն200 ng/g. Agreement was higher between self-reported alcohol use at Ն19 weeks and marker combinations that included EtG. Among the 58 women reporting drinking after 19 weeks, 48 were EtG positive with a median (range) concentration of 1101 ng/g (7.2-103 716), 16 were EtS positive with a concentration of 14 ng/g (2.8 -408), and 37 were positive for 1 or more FAEE with 7 FAEE summed concentrations ranging from 0.081 to 256 nmol/g (only 13 were Ն2 nmol/g).
PERFORMANCE CHARACTERISTICS OF SELF-REPORTED EXPOSURE AND MECONIUM MARKERS
With EtG Ն30 ng/g as the gold standard condition, clinical sensitivity and specificity of self-reported drinking Ն19 weeks' gestation were 81.8% (95% CI 71.8 -92.0) and 75.2% (95% CI 63.2-86.8), respectively. Selfreported drinking Ն19 weeks' gestation yielded similar performance, with EtG and EtS at their LOQs for clinical sensitivity (68.6%, 95% CI 57.7-79.4, and 69.6%, 95% CI 50.8 -88.4, respectively), although when EtG was Ն5 ng/g, self-reported drinking Ն19 weeks had higher specificity (73.0%, 95% CI 58.7-87.3) compared with EtS Ն2.5 ng/g (50.0%, 95% CI 39.3-60.7). Selfreported drinking Ն19 weeks demonstrated 64.9% sensitivity (95% CI 49.5-80.2) and 51.4% specificity (95% CI 39.7-63.1) with the 4 FAEE summation (ethyl myristate, palmitate, oleate, and stearate) Ն200 ng/g; these performance measures were higher than those for the 7 and 9 FAEE summations.
With meconium EtG Ն30 ng/g as the gold standard condition, there were 45 true positives, 39 true negatives, 13 false positives, and 10 false negatives (Table 4) . Among the 13 false-positive samples (EtG Ͻ30 ng/g but women reported drinking after 19 weeks), women reported LDD between 19.3 and 37.4 weeks. Three had detectable EtG (7.2-24 ng/g) below the 30 ng/g cutoff (1 had some individual FAEE detected), 2 others were EtS- The 3 EtG-positive samples were from women who reportedly all stopped drinking during week 34. Women whose infants had the 3.2 and 13 ng/g EtS-positive samples stopped drinking during week 20 and 37, respectively. The woman whose infant had meconium 7 FAEE sum >2 nmol/g stopped drinking at 27.1 weeks.
f
The false negative with 6230 ng/g EtG, 13 ng/g EtS, and high FAEE reportedly stopped drinking at 5 weeks' gestation. During the 31 days before stopping, she drank every day with an average of 7 drinks/day reported.
g Data from 7 women (70%) were included here. The remaining 3 women reported no drinking in any trimester.
positive only, 2 others had some individual FAEE detected, and another had a 7 FAEE sum Ͼ2 nmol/g (10.6 nmol/g); no markers were detected in the other 5 (Table  4) . Of the 10 self-report-positive, EtG-negative samples, only 5 women reported third-trimester drinking; median GA was 33.6 (30.6 -37.4) weeks, and DPDD for LDD was 7.0 (0.8 -13.8) standard drinks. Among the 5 women reporting second-but no third-trimester drinking, median GA was 25.9 (19.3-27.1) weeks, and DPDD for LDD was 1.6 (0.1-11.6) standard drinks. All 10 women reported 1-3 drinking days during the 31 days before LDD. In the 10 false-negative samples (EtG Ն30 ng/g but women reported no alcohol consumption during pregnancy or cessation before week 19), 6 samples had summed 7 FAEE meconium concentrations Ն2 nmol/g (Table 4 ).
DOSE-CONCENTRATION RELATIONSHIPS
A statistically significant dose-concentration relationship was observed between self-reported DPDD after 19 weeks' gestation and meconium EtG Ն30 ng/g, adjusted for GA at LDD (model P Ͻ 0.0001, all DPDD P Ͻ 0.01, GA P ϭ 0.42); the model had good discrimination (c-statistic 0.81) and was well calibrated ( 2 ϭ 9.3, P ϭ 0.23). For selfreported DPDD between Ͼ0 and Յ3, the odds of observing meconium EtG Ն30 ng/g was 9.1 times higher (95% CI 1.8 -45.8) than for women reporting no drinking. Odds of meconium EtG Ն30 ng/g increased to 22.6 (95% CI 6.2-82.0) when considering self-reported DPDD between Ͼ3 and Յ10 and to 29.4 (95% CI 2.9 -295.6) when considering self-reported DPDD Յ10, compared with women reporting no drinking. No significant changes were observed when the meconium exposure period was modified on the basis of maternal self-reported drinking at Ն12, Ն20, or Ն28 weeks.
Discussion
Less is known about EtG and EtS meconium markers in comparison to FAEE, and few studies have compared PAE detection capability among markers. Our study is the most thorough comparison to date of meconium EtG and EtS concentrations with FAEE concentrations and detailed, prospective maternal self-reported drinking during pregnancy. Five prior studies collected self-reported maternal alcohol consumption and meconium EtG, EtS, and FAEE. However, high underreporting in 4 of these studies did not permit the authors to compare self-reported PAE with meconium EtG and EtS; instead, meconium EtG and EtS cutoffs were optimized on the basis of meconium FAEE comparison (12, 14, 15, 18 ) . In those studies, the proposed EtG meconium cutoffs (274, 333, and 444 ng/g) were derived from comparisons to summed 5-7 meconium FAEE concentrations (11, 12, 14 ) . This approach is inadequate owing to FAEE limitations and bias, including instability and diet concerns. A recent Franconian Maternal Health Evaluation Studies report suggested that maternal selfreport better agreed with meconium EtG than individual FAEE, supporting the concept that FAEE should not be used as the precedent (33 ) . Our study is unique in its simultaneous FAEE, EtG, and EtS quantification in the same 0.1-g meconium sample, achievable owing to our combined analytical method (26 ) , permitting accurate clinical sensitivity and specificity comparisons between self-reported exposure and meconium markers.
Our high clinical sensitivity and specificity indicate that accurate PAE classification in infants is optimal with EtG Ն30 ng/g. We found a significant dose-concentration relationship between maternal self-reported DPDD after 19 weeks and meconium EtG Ն30 ng/g, providing evidence that this marker accurately represents increasing PAE. Our results suggest that meconium EtG concentration Ն30 ng/g is the most effective cutoff for PAE identification. DPDD, not drink timing after 19 weeks, was significantly associated with meconium EtG Ն30 ng/g.
Prior studies demonstrated that self-reported exposures could suffer from limited information regarding timing, quantity, and frequency, as well as recall bias in retrospective investigations. The TLFB method is a widely accepted tool to collect detailed and reliable self-reported exposure (29, 34 ) . This method was tailored to our studied populations and modified to collect more precise, serial information throughout pregnancy, allowing evaluation of individual drinking patterns across time (27 ) .
Our clinical sensitivity and specificity evaluation indicated that maternal self-reported PAE agreed best with meconium EtG Ն30 ng/g (81.8% sensitivity, 75.0% specificity, ϭ 0.569). The currently accepted 7 FAEE summation Ն2 nmol/g cutoff achieved only 52.0% sensitivity and 45.1% specificity. When considering marker cutoff combinations, meconium EtG alone Ն30 ng/g proved superior; of the 13 samples with EtG Ͻ30 ng/g from infants of women who reported any drinking beyond 19 weeks, only 1 had a 7 FAEE summed concentration Ն2 nmol/g. The better performance of EtG compared with FAEE may have resulted from FAEE limitations, including postcollection meconium instability (26 ) and olive oil variability in maternal diet (9 ) . Weak correlations between EtG and individual and summed FAEE concentrations (Table 2 ) may reflect the markers' different formation pathways and possibly different meconium incorporation mechanisms.
Previous meconium EtG and EtS reports did not find EtS alone in meconium; when detected, EtS was always present with EtG (12, 14 ) . However, EtS is often present without EtG in urine (35, 36 ) . This study is the first report of EtS-positive, EtG-negative meconium samples. In 1 case, 61 ng/g EtS was detected with high FAEE (13.9 nmol/g summed 7 FAEE). In the other 4 cases, EtS was the only detectable marker. This may be explained by our low EtS LOQ compared to our other markers, although our EtS LOQ was higher than the 1 ng/g previously reported (13 ) . EtG-negative meconium also may have resulted from reduced maternal EtG formation due to genetic UGT polymorphisms (37 ) or liver damage from heavy alcohol consumption. UGT polymorphism studies indicated that cannabinoids, specifically cannabidiol, negatively impacted ethanol glucuronidation activity (37 ) . EtS-positive, EtGnegative meconium could result from increased fetal sulfotransferase activity compared to fetal glucuronidation capacity. Fetal liver sulfotransferase activity varies on the basis of isoform and gestational period (25 ) ; some isoforms demonstrate higher activity during gestation compared with infancy (25 ) , whereas fetal UDPglucuronosyltransferase activity is limited, with most activity beginning after birth (23 ) . Urinary EtG/EtS studies demonstrated that bacteria-infected urine was capable of both EtG hydrolysis and formation (38 ) ; urinary bacterial meconium contamination may explain some positive self-report, EtG-negative meconium (EtG hydrolysis) and negative self-report, EtG-positive meconium (EtG formation). Urine and postmortem tissue EtS was stable (38, 39 ) , providing a possible explanation for some EtS-only-positive urine. Most South Africa samples were collected at home within 48 h and returned to the study site; bacterial contamination during home collection could also explain these findings.
Variability in EtG and EtS formation and placental transfer of ethanol and these markers may explain the wide EtG/EtS ratio range observed (3.3-2151). The low 3.3 EtG/EtS ratio resulted from 19 ng/g EtG and 5.7 ng/g EtS from a self-reported nondrinker. The highest EtG/EtS ratio resulted from 18 286 ng/g EtG and 8.5 ng/g EtS from a PAE infant exposed to 12.7 and 5.6 DPDD in the second and third trimesters, respectively.
Our study had some limitations. Our small feasibility design, as opposed to a true random selection study design, and population demographics require that the proposed meconium EtG Ն30 ng/g cutoff be validated in larger samples from other populations. A larger sample would also offer an opportunity to further investigate the role of EtS in identifying PAE.
Our study demonstrates the importance of identifying alcohol-exposed infants via both maternal self-report and objective biomarkers. Meconium biomarkers primarily capture drinking in the third trimester and some second-trimester exposure, whereas maternal self-report can identify earlier gestational exposure missed by meconium. In our study, most negative self-report, meconium EtG Ն30 ng/g cases demonstrated strong PAE evidence; EtG's validity was confirmed by the presence of additional meconium markers. These women likely underreported their drinking behavior, demonstrating limitations of self-report reliance, or results could be explained by consumption of other products containing ethanol not identified with our TLFB assessment, or bacterial contamination at collection. However, our positive selfreport, meconium EtG Ͻ30 ng/g cases demonstrate that some drinking behaviors may not be accurately identified with meconium analysis. Increasing meconium formation before birth may explain these findings, as increasing amounts of negative meconium may dilute limited or previously EtG-positive meconium. Therefore, selfreport should also be included in studies using meconium biomarkers.
In conclusion, maternal self-report was correlated with meconium EtG, EtS, and FAEE concentrations in the same 0.1-g meconium sample. Optimal clinical sensitivity (81.8%) and specificity (75.0%) were observed between maternal self-reported alcohol consumption after 19 weeks' gestation and meconium EtG Ն30 ng/g. These data should help inform clinicians, clinical chemists, and toxicologists on meconium alcohol marker interpretation and PAE identification.
